PMID- 8148492
OWN - NLM
STAT- MEDLINE
DCOM- 19940510
LR  - 20071114
IS  - 0925-5710 (Print)
IS  - 0925-5710 (Linking)
VI  - 58
IP  - 3
DP  - 1993 Oct
TI  - In vivo effects of purified recombinant human macrophage colony-stimulating 
      factor in combination with local hyperthermia on tumor progression in B16a 
      melanoma bearing mice.
PG  - 139-52
AB  - Recombinant human (rhu) macrophage colony-stimulating factor (M-CSF) was 
      evaluated, alone or in combination with local hyperthermia (LH), for their 
      antitumor effects in mice inoculated with B16a melanoma cells. Several tumor 
      related parameters and other hematopoietic and immunologic parameters were 
      evaluated 5 weeks after subcutaneous (s.c.) inoculation of tumor cells into the 
      right limbs of C57BL/6J male mice. RhuM-CSF was administered at 20 
      micrograms/injection, s.c., twice a day for 5 days/week for 2 weeks beginning 6 
      days after tumor cell inoculation and LH (43 +/- 0.2 degrees C) was given for 30 
      min twice/week for 2 weeks. Combined therapy prolonged survival of mice and 
      caused significant inhibition of tumor growth, as measured by the volume or size 
      of primary tumor, number and size of lung metastases, and chromatin fragment (CF) 
      formation in tumor bearing mice, while treatment with M-CSF or LH alone had less 
      or no effect. Combined therapy also resulted in increased numbers of splenic 
      T-lymphocytes and the ratio of T-helper/suppressor cells, restoration of natural 
      killer (NK) cell activity, increased numbers of peritoneal macrophages and their 
      erythrophagocytosis capacity, and increased release or production of tumor 
      necrosis factor (TNF)-alpha, but not interleukin (IL)-1 alpha or IL-6. These 
      results add to previous evidence that M-CSF might be a relevant therapeutic agent 
      in combination with other therapies in the treatment of certain malignant 
      diseases.
FAU - Lu, L
AU  - Lu L
AD  - Department of Medicine (Hematology/Oncology), Indiana University School of 
      Medicine, Indianapolis.
FAU - Xiao, M
AU  - Xiao M
FAU - Wu, B
AU  - Wu B
FAU - Wang, W X
AU  - Wang WX
FAU - Yan, W R
AU  - Yan WR
FAU - Broxmeyer, H E
AU  - Broxmeyer HE
FAU - Shen, R N
AU  - Shen RN
LA  - eng
GR  - R01 HL46549/HL/NHLBI NIH HHS/United States
GR  - R01 HL49202/HL/NHLBI NIH HHS/United States
GR  - R37 CA36464/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Recombinant Proteins)
RN  - 81627-83-0 (Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - Combined Modality Therapy
MH  - Humans
MH  - Hyperthermia, Induced
MH  - *Macrophage Colony-Stimulating Factor/isolation & purification/*therapeutic use
MH  - Male
MH  - Melanoma, Experimental/pathology/*therapy
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Recombinant Proteins/isolation & purification/therapeutic use
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
PST - ppublish
SO  - Int J Hematol. 1993 Oct;58(3):139-52.